- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed against the S&P 500 and did not exceed that of the Biotechnology industry. The net income has decreased by 3.2% when compared to the same quarter one year ago, dropping from -$1.59 million to -$1.64 million.
- Net operating cash flow has declined marginally to -$1.58 million or 0.18% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
- OGEN's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 32.21%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ORAGENICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- The gross profit margin for ORAGENICS INC is rather high; currently it is at 65.58%. Regardless of OGEN's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, OGEN's net profit margin of -763.25% significantly underperformed when compared to the industry average.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. The Drugs industry as a whole closed the day down 2.8% versus the S&P 500, which was down 0.5%. Laggards within the Drugs industry included Aoxing Pharmaceutical ( AXN), down 4.5%, Reliv' International ( RELV), down 1.8%, Oragenics ( OGEN), down 3.4%, Celator Pharmaceuticals ( CPXX), down 1.6% and Heat Biologics ( HTBX), down 1.5%. TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today: Oragenics ( OGEN) is one of the companies that pushed the Drugs industry lower today. Oragenics was down $0.07 (3.4%) to $1.93 on light volume. Throughout the day, 9,116 shares of Oragenics exchanged hands as compared to its average daily volume of 29,000 shares. The stock ranged in price between $1.87-$1.97 after having opened the day at $1.88 as compared to the previous trading day's close of $2.00. Oragenics, Inc. focuses on the discovery, development, and commercialization of various technologies associated with oral health, antibiotics, and other general health benefits. Oragenics has a market cap of $72.2 million and is part of the health care sector. Shares are down 28.9% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst who rates Oragenics a buy, no analysts rate it a sell, and none rate it a hold. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreet Ratings rates Oragenics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Highlights from TheStreet Ratings analysis on OGEN go as follows: